Our profiling and comparison with the actions of conolidine and cannabidiol with recognized pharmacological agents predicted a MOA shared with Cav2.two channel blocker, ω-conotoxin CVIE. Most recently, it's been recognized that conolidine and the above derivatives act within the atypical chemokine receptor 3 (ACKR3. Expressed in very similar parts https://hatshepsutw267nlj8.eedblog.com/profile